Provider review
Strut Health Review: The NAD+ Page That Calls a Coenzyme a Peptide
Strut Health sells two peptides as its longevity line, and the evidence underneath them is thinner than any label on the site suggests. Sermorelin — injectable at $119, an oral lozenge at $99 — has no ClinicalTrials.gov record naming it as an intervention and no randomised-controlled-trial publication in PubMed, established here across six query forms with controls that fired correctly. NAD+ at $149 is sold under a heading that calls it "a peptide that signals your own pituitary gland", which is the sermorelin template left unedited on a molecule that is neither a peptide nor active on the pituitary; the same block ships on the men's and the women's page. Its ED tablet lists "Apomorphine OR PT-141" among its actives without saying which you receive. Set against that: Strut prints "Compounded medications are not FDA-approved" on its product pages, publishes full contraindication and side-effect blocks that most of this category omits, and holds an open FDA warning letter from February 2026 about exactly the kind of labelling the site has since cleaned up.
Compounded only
Phase 3 trials
Not named
February 2026
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens www.struthealth.com. A link is not a recommendation to take anything.
Provenance
What Strut Health actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Injectable Sermorelin Peptide Therapy — "Starting at $119" for 9 mg at 2.5 mg/mL. Strut bills "every 30 or 90 days" under its Terms §20, and no non-subscription price is reachable — checkout gates on email and phone before a total is shown.
- Oral Sermorelin Peptide Therapy (lozenge) — "Starting at $99" for 30 lozenges. Same 30- or 90-day billing as the injectable.
- NAD+ Injection — "Starting at $149" for 500 mg at 200 mg/mL.
- Injectable Semaglutide (compounded, with vitamin B6) — "As low as $149", which is a subscription rate; no one-off price is reachable before the intake collects an email and phone number.
- Compounded Injectable Tirzepatide (with vitamin B6) — "As low as $199"; the page's own 30-day supply card reads $325. The $6.63-a-day figure printed under $325 belongs to the $199 rate.
- Super Strut: 4-in-1 Dissolvable ED Tablet — "Starting at $79/mo" for 10 tablets.
Evidence
Is there a human trial at all?
One row per product, graded on how far the published human evidence goes for the use it is sold for — not for the molecule in general. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
3
Products with a human trial
Out of 6 reviewed here.
4
Registry records cited
Each read live from ClinicalTrials.gov, never from memory.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Strut Health’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Injectable Sermorelin Peptide TherapySermorelin · Compounded (503A)No trial supports this claim
“A modern therapy designed to help your body naturally boost growth hormone. May support deeper sleep, faster recovery, mental clarity, fat metabolism, lean muscle mass, energy, mood, and metabolic health. The intelligent way to manage age-related decline.”
No human trial
As of 10 August 2026, a ClinicalTrials.gov v2 search returns NO interventional record naming sermorelin as the intervention, in any phase and at any status. Six query forms were run — intervention "sermorelin", "sermorelin acetate", "GHRH(1-29)", "GHRH 1-29", "growth hormone releasing hormone 1-29" and "Geref" (its withdrawn brand name) — plus a free-text search of every field. The intervention search does return 27 studies, and every one of them is a DIFFERENT molecule: tesamorelin (TH9507/Egrifta), GHRH(1-44), or an unspecified "GHRH" used as a diagnostic stimulation agent. The searches discriminate: run identically, tirzepatide returns 158 records naming it, tesamorelin 17 and bremelanotide 10. In PubMed, "sermorelin" appears in 24 titles or abstracts and ZERO of them carry the randomised-controlled-trial or clinical-trial publication type, against 126, 21 and 11 for the same three controls. The single record combining sermorelin with ageing or body composition is a narrative review (PMID 32257855), not a trial.
Eight outcomes are promised in one sentence — sleep, recovery, mental clarity, fat metabolism, lean muscle, energy, mood and metabolic health — for a molecule with no human trial record of any kind. "May support" is doing heavy lifting, but the page is not hedging a weak result; there is no result. The mechanistic half is fair: sermorelin is a GHRH analogue and it does act on the pituitary, which is more than can be said for what this site found on the NAD+ page. What has never been measured in a registered trial is whether that mechanism produces any of the eight things listed.1,2
Oral Sermorelin Peptide Therapy (lozenge)Sermorelin · Compounded (503A)No trial supports this claim
“A modern therapy designed to help your body naturally boost growth hormone. May support deeper sleep, faster recovery, mental clarity, fat metabolism, lean muscle mass, energy, mood, and metabolic health. The intelligent way to manage age-related decline.”
No human trial
The same searches that returned no sermorelin record at all — six intervention forms and a free-text pass on ClinicalTrials.gov, and a PubMed publication-type filter, all run 10 August 2026 with tirzepatide, tesamorelin and bremelanotide as positive controls — necessarily return none for a lozenge either. Stated separately because the route matters and is the larger gap: no registered trial establishes that sermorelin is absorbed intact across the oral or sublingual mucosa in a quantity that reaches the pituitary. Peptides are cleaved by peptidases and, for the injectable form, Strut's own page instructs subcutaneous administration.
This is the injectable page's sentence, word for word, on a product delivered a completely different way — the same eight promised outcomes at $99 instead of $119. Two separate things are unevidenced here rather than one. The molecule has no trial record, and the route has no absorption study behind it in the registry. Strut's own FAQ quietly concedes the second point when it advises taking the lozenge "on an empty stomach" and avoiding food or drink afterwards "to allow for better absorption" — a workaround for a problem the product page does not mention.1,2
NAD+ InjectionNAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)No trial supports this claim
“NAD+ (Nicotinamide Adenine Dinucleotide) therapy is designed to replenish a vital coenzyme that naturally declines with age. This coenzyme plays a key role in energy metabolism, DNA repair, and cellular resilience. This therapy may help support more natural energy, clearer focus, and long-term wellness. […] Meet NAD+: A peptide that signals your own pituitary gland. Supports your body's natural hormone production.”
No human trial
As of 10 August 2026, a ClinicalTrials.gov v2 intervention search for injected NAD+ in humans returns no completed randomised trial supporting a restoration-of-function claim, and a PubMed search for "nicotinamide adenine dinucleotide" combined with injection or subcutaneous, filtered to the randomised-controlled-trial publication type, returns zero records. The substantial human literature concerns ORAL precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route.
The page contradicts itself within one screen. Its intro correctly calls NAD+ "a vital coenzyme"; its "Meet NAD+" block calls it "a peptide that signals your own pituitary gland" and credits it with supporting "natural hormone production". NAD+ is a dinucleotide, not a peptide, and nothing about it acts on the pituitary — that sentence is the sermorelin template left unedited, and it ships identically on the women's page, so it is a shipped template rather than a slip. Underneath the error, the substantive claims — energy, focus, "long-term wellness" — have no completed human trial of injected NAD+ behind them.3
Injectable Semaglutide (compounded, with vitamin B6)Semaglutide · Compounded (503A)Claim reaches past the trials
“GLP-1 compounded weight management therapy with Semaglutide. How Semaglutide might help: Suppress Appetite. Improves Health. Lose Weight. Designed to suppress appetite and improve glycemic control.”
Phase 3 trials
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Tested the approved 2.4 mg product. No compounded semaglutide from any seller has been through a registered trial.
Appetite suppression, glycaemic control and weight loss are all genuinely established for semaglutide at phase 3, so the substance of this page is sound and it is the best-evidenced thing Strut sells. Two things push it past the trials. "Improves Health" is an unbounded claim with no endpoint attached, carried on an asterisk that resolves to nothing on the page. And no trial is named anywhere — STEP 1 tested the approved finished product, while what Strut dispenses is a compounded preparation with added vitamin B6 that has never been in a registered trial, a distinction the page does not draw.4
Compounded Injectable Tirzepatide (with vitamin B6)Tirzepatide · Compounded (503A)Claim reaches past the trials
“GLP-1/GIP dual receptor agonist compounded weight management therapy with Tirzepatide. A Powerful Solution for Your Health and Weight Management Goals. Designed to reduce appetite and improve glycemic control. How Tirzepatide might help: Regulate Appetite. Support Metabolic Health. Enhance Weight Loss.”
Phase 3 trials
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Tested the approved product at the highest tolerated dose over 72 weeks.
The pharmacology is stated correctly — tirzepatide is a GIP/GLP-1 dual agonist, and appetite and glycaemic effects are established at phase 3. "A Powerful Solution for Your Health" is marketing rather than a claim that can be checked, and as with semaglutide no trial is named and the compounded preparation is not the product SURMOUNT-1 tested. The page's arithmetic is also wrong in the reader's disfavour: under a heading reading "Transparent Pricing", the card prints "30 DAY SUPPLY — $325 — Just $6.63". $325 over thirty days is $10.83 a day. $6.63 a day is the "as low as $199" rate from the top of the same page, printed beneath a different number.5
Super Strut: 4-in-1 Dissolvable ED TabletBremelanotide (PT-141) or apomorphine, with oxytocin · Compounded (503A)No trial supports this claim
“Introducing the world's first and only 4-in-1 ED tablet. Experience a powerful, fast-acting solution for enhanced performance and confidence. Fast-acting formula works in as little as 15 minutes. Active for up to 36 hours. Active Ingredients: Tadalafil, Vardenafil, Apomorphine OR PT-141, Oxytocin.”
Phase 3 trials
- NCT02333071 RECONNECT Study 1 — Phase 3, completed, n=723. Bremelanotide in premenopausal women with hypoactive sexual desire disorder. No male participants.
- NCT02338960 RECONNECT Study 2 — Phase 3, completed, n=714. The second registration trial, same population. The approval that followed is for premenopausal women only.
Two distinct problems, and the second is unusual enough to be worth stating plainly. First, the peptide: the phase 3 evidence for bremelanotide is entirely in premenopausal women with hypoactive sexual desire disorder, and the approved product's label carries two consecutive Limitations of Use — "not indicated… in men" and "not indicated to enhance sexual performance" — which together negate the use this tablet is sold for. Second, the ingredient list reads "Apomorphine OR PT-141". Those are different drug classes: a dopamine agonist and a melanocortin receptor agonist, with different mechanisms, different side-effect profiles and different interactions. A buyer cannot tell from the page which of the two they will be swallowing. The tadalafil and vardenafil in the tablet are well-evidenced PDE5 inhibitors and are not what is being questioned here.6,7
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named anywhere on struthealth.com — checked across the 132 pages in its own sitemap. The language is consistently anonymous: "partner pharmacy", "pharmacy network", "U.S. Pharmacy & Medicines". That omission sits directly on top of the open FDA letter, which is precisely about who the compounder is: FDA's finding was that Strut's product labels "identify 'Strut' on the pictured label, suggesting Strut is the compounder of those drugs when in fact it is not." ⚠ The footer carries ACHC and PCAB accreditation badges — both of them PHARMACY accreditations — with no accredited entity, no certificate number and no link, displayed by a company FDA has stated is not the compounder. A reader cannot tell whether those badges belong to Strut, to an unnamed partner pharmacy, or to neither. Strut's own corporate identity is published plainly: Strut Health, LLC, 701 Commerce Street, Dallas, TX 75202, with Dr. Simal Patel, MD named as founder and CEO, and the clinical entity given in its own documents as both Titan Health, P.A. and "Titan Medical Group".
Read on August 2026 from https://www.struthealth.com/mens-wellness-longevity/injectable-sermorelin-peptide-therapy
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, batch record, potency result, sterility result, named laboratory or lot lookup is published anywhere on the site, for any product. What Strut does publish instead is unusually good and worth separating from that: every product page carries a full Warnings, Contraindications, Drug Interactions and Side Effects block written at a level a patient can act on — the sermorelin page names tumour risk, insulin resistance, thyroid interference and pregnancy exclusion; the NAD+ page names cardiovascular, autoimmune and metabolic conditions requiring monitoring. Most sellers in this category publish none of that. It is safety labelling, not quality evidence, and it does not tell a reader whether the vial they receive was tested. ⚠ The ACHC and PCAB badges in the footer are the closest thing on the site to a quality assertion, and they name no entity and carry no number, so nothing about them can be checked.
Read on August 2026 from https://www.struthealth.com/mens-wellness-longevity/mens-nad-therapy
Licensing
Licensed to dispense, and where
Coverage
All states except Arkansas
Read the full licensing claim
Strut ships to every state except Arkansas — an exclusion it publishes itself rather than one inferred from a funnel, and one of the few named exclusions anywhere in this roster. Its clinicians are described as "U.S. Licensed & Board Certified Physicians" with no licence numbers published; the prescribing entity appears in Strut's own documents under two names, Titan Health, P.A. and "Titan Medical Group", with an Openloop/Junction backend behind the intake. Billing runs "every 30 or 90 days" under Terms §20 and no non-subscription price is reachable, because checkout gates on an email address and phone number before any total is shown.
Named as outside that footprint
Read on August 2026 from https://www.struthealth.com/terms-conditions
Regulatory
The FDA warning letter
Issued February 2026
Strut Health, LLC dba Strut — 721448. Concerns marketing and labelling.
Read the full allegation
FDA reviewed struthealth.com in December 2025 and cited two things under FD&C Act sections 502(a) and 502(bb). First, that the compounded semaglutide and tirzepatide products "displayed on your website identify 'Strut' on the pictured label, suggesting Strut is the compounder of those drugs when in fact it is not." Second, website claims including "Generic Zepbound, Mounjaro" and "Semaglutide is the active ingredient in the brand medications." Both findings concern labelling and advertising. The letter makes no allegation about sterility, potency, contamination or product quality.
What has changed since
Checked 10 August 2026. All three cited phrases are gone from the live site, and Strut's product pages now carry "Compounded medications are not FDA-approved. This compound has not been evaluated by the FDA for safety or efficacy." No close-out notice has been issued, so the letter remains open nearly six months on. FDA publishes close-outs in a dedicated column of the warning-letter index; the control used to confirm that column reads correctly is Belmar's letter of 31 March 2023, closed out 30 October 2023.
Assessment
What holds up, and what does not
- It prints the sentence most of this category avoids: "Compounded medications are not FDA-approved. This compound has not been evaluated by the FDA for safety or efficacy", on the product pages themselves rather than buried in terms.
- Full contraindication and side-effect blocks on every product page — tumour risk, insulin resistance and thyroid interference on sermorelin; cancer history, liver and kidney disease on NAD+ — written to be acted on rather than to satisfy a lawyer.
- It names a specific state exclusion, Arkansas, instead of claiming all fifty and qualifying it later. Almost nothing else in this roster does that.
Show 4 more
- The corporate identity is published in full: Strut Health, LLC at 701 Commerce Street, Dallas, with a named physician founder, Dr. Simal Patel, MD.
- It responded to the FDA letter substantively. All three cited phrases are gone from the live site and the compounding disclaimer now leads the weight-loss pages.
- Its GLP-1 claims are the honest core of the catalogue — appetite suppression and glycaemic control are established at phase 3 for both molecules it sells.
- The protocol details a patient needs are on the page: strengths and volumes (9 mg at 2.5 mg/mL; 500 mg at 200 mg/mL), the 5-days-on, 2-days-off sermorelin cycle, and refrigerated storage at 36–46°F.
- The NAD+ page calls the molecule "a peptide that signals your own pituitary gland" — it is a dinucleotide and does not act on the pituitary. The same block ships on the men's and the women's page, and the same page's own intro calls it a coenzyme.
- Sermorelin, its flagship peptide at both $119 and $99, has no ClinicalTrials.gov record naming it as an intervention and no randomised-trial publication in PubMed — established across six query forms with controls that returned 158, 17 and 10 records.
- The oral sermorelin lozenge carries the injectable's sentence unchanged, for a route with no absorption study behind it in the registry.
Show 8 more
- Super Strut's actives read "Apomorphine OR PT-141" — two different drug classes — and the page never says which one a buyer receives.
- It sells a compounded bremelanotide preparation to men for performance, when the approved product's label says in consecutive sentences that it is not indicated in men and not indicated to enhance sexual performance.
- No pharmacy is named across 132 pages, while the open FDA letter is specifically about the site suggesting Strut is the compounder when it is not.
- ACHC and PCAB pharmacy-accreditation badges sit in the footer with no entity, number or link — displayed by a company FDA has stated is not the compounder.
- No certificate of analysis, batch record, potency or sterility result is published for any product.
- Under a heading reading "Transparent Pricing", the tirzepatide card prints "$325" and "Just $6.63" together. $325 over thirty days is $10.83 a day; $6.63 is the other price on the page.
- No non-subscription price is reachable. Billing is "every 30 or 90 days" and checkout collects an email address and phone number before showing a total.
- FDA warning letter 721448 is open — issued 20 February 2026 with no close-out. It concerns labelling, not product quality, and it is disclosed here rather than treated as disqualifying.
Verdict
The bottom line
Strut Health is better than most of this category at the things a lawyer would tell it to do, and worse than it looks at the thing this site exists to check. Its contraindication blocks are genuinely useful, it prints the not-FDA-approved sentence on the product page, it names the one state it cannot ship to, and it fixed what FDA wrote to it about. Then its NAD+ page calls a coenzyme "a peptide that signals your own pituitary gland" — twice, on two pages — and its flagship peptide turns out to have no human trial record at all, in either registry, under any name. If you are buying semaglutide or tirzepatide here, the claims are broadly sound and the price on the card is not the price in the arithmetic. If you are buying sermorelin, you are paying $119 a month for eight promised outcomes and a molecule that no registered trial has ever tested. And if you are buying Super Strut, the page will not tell you whether the tablet contains a melanocortin agonist or a dopamine agonist, which is not a detail.
Opens www.struthealth.com. A link is not a recommendation to take anything.
The page that forgot which molecule it was selling
Strut's NAD+ page opens correctly. "NAD+ (Nicotinamide Adenine Dinucleotide) therapy is designed to replenish a vital coenzyme that naturally declines with age. This coenzyme plays a key role in energy metabolism, DNA repair, and cellular resilience."
That is accurate. NAD+ is a coenzyme — specifically a dinucleotide — and it does all three of those things.
Scroll two screens. Under a heading reading "Meet NAD+", the page says:
"A peptide that signals your own pituitary gland. Supports your body's natural hormone production."
NAD+ is not a peptide. It has no amino acids in it. It does not signal the pituitary gland, and it is not involved in hormone production in the sense that sentence intends.
What it is, is the sermorelin block. Open Strut's injectable sermorelin page and the identical three lines appear under "Meet Sermorelin Therapy", where every word of them is true. Somebody built the NAD+ page from the sermorelin template, changed the heading, and left the body.
This is not a rendering artefact and not a stale cache. It is in the served HTML, and it is on both the men's NAD+ page and the women's. A template that ships twice is a published claim.
Full analysis — 5 more sectionsSermorelin: eight promises, no trial · "Apomorphine OR PT-141" · What Strut does better than its neighbours · The letter, and what it was actually about · What this means if you are buying
Sermorelin: eight promises, no trial
Sermorelin is Strut's longevity line — $119 for a 9 mg injectable vial, $99 for thirty lozenges. Both pages carry the same sentence:
"A modern therapy designed to help your body naturally boost growth hormone. May support deeper sleep, faster recovery, mental clarity, fat metabolism, lean muscle mass, energy, mood, and metabolic health."
Eight outcomes. Here is what the registry holds for the molecule delivering them.
A ClinicalTrials.gov search for sermorelin as an intervention returns twenty-seven studies, and not one of them names sermorelin as the intervention. 1 Every hit is a different molecule that the registry's synonym expansion has swept in: tesamorelin — sold as Egrifta, a genuinely approved GHRH analogue — or GHRH(1-44), or an unspecified "GHRH" used as a diagnostic stimulation agent for pituitary testing. Sermorelin is GHRH(1-29). It is not any of those.
Six query forms were tried: "sermorelin", "sermorelin acetate", "GHRH(1-29)", "GHRH 1-29", "growth hormone releasing hormone 1-29", and "Geref", the brand name under which sermorelin was once approved and has since been withdrawn. A free-text search across every field in every record was run as well. Zero.
The obvious worry with a finding like that is a broken search. So the same queries were run for three molecules that should be there. Tirzepatide returns 158 records naming it as the intervention. Tesamorelin returns 17. Bremelanotide returns 10. The instrument works.
PubMed agrees. "Sermorelin" appears in twenty-four titles or abstracts, and zero of them carry the randomised-controlled-trial or clinical-trial publication type. 2 The same filter returns 126 papers for tirzepatide, 21 for tesamorelin and 11 for bremelanotide. The single paper that pairs sermorelin with ageing or body composition is a narrative review in Translational Andrology and Urology, not a trial.
None of that is Strut's fault. It is a fact about the molecule, and it is equally true of every other company in this category selling sermorelin — which is most of them. What belongs to Strut is the decision to promise eight specific outcomes from it, on two products, at two prices, with no qualification anywhere on either page.
The lozenge compounds the problem. It carries the injectable's sentence verbatim, for a delivery route with no absorption study behind it. Peptides are cleaved by peptidases; getting one across the oral mucosa intact and in useful quantity is the hard part. Strut's own FAQ half-concedes this, advising patients to take the lozenge "on an empty stomach" and to avoid eating or drinking afterwards "to allow for better absorption" — a workaround for a difficulty the product page never raises.
"Apomorphine OR PT-141"
Super Strut is sold as "the world's first and only 4-in-1 ED tablet", $79 a month for ten tablets, "fast-acting" and "active for up to 36 hours". Its active ingredients are listed as:
"Tadalafil. Vardenafil. Apomorphine OR PT-141. Oxytocin."
Two of those four are uncontroversial. Tadalafil and vardenafil are approved PDE5 inhibitors with large trial programmes, and nothing here questions them.
The third slot is the problem, twice over.
PT-141 is bremelanotide, and the evidence for it runs in a direction the page does not acknowledge. Its two phase 3 registration trials, RECONNECT 1 and 2, enrolled 723 and 714 premenopausal women with hypoactive sexual desire disorder. 7 The approval that followed is Vyleesi, and the Vyleesi label carries two Limitations of Use in consecutive sentences: "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men. VYLEESI is not indicated to enhance sexual performance." 6 Strut sells it to men, for performance.
That is not ordinary off-label prescribing, which is lawful and often good medicine. Off-label use rests on evidence the label has not caught up with. Here the label is describing the absence of evidence, and the registry agrees with the label.
And then there is the "OR". Apomorphine is a dopamine agonist. Bremelanotide is a melanocortin receptor agonist. They are different drug classes with different mechanisms, different adverse-effect profiles and different interactions — apomorphine in particular is associated with nausea and with orthostatic hypotension. The page offers no way to find out which one is in the tablet you are prescribed. For a product taken sublingually alongside two PDE5 inhibitors, that is not a formulation detail.
What Strut does better than its neighbours
It would be easy to read the above as a company being careless, and the rest of the site does not support that reading.
Strut publishes real safety labelling. Its sermorelin pages carry a warning that sermorelin and growth hormones "may have a negative effect on tumor growth" and should not be used by anyone with cancerous or benign tumours; that it may raise blood glucose and worsen insulin resistance; that it may interfere with thyroid function. The NAD+ page names cancer treatment, liver disease, kidney disease and uncontrolled diabetes as things to disclose. Most sellers in this category publish nothing of the kind, and Strut's blocks are written to be acted on.
It prints, on the product page rather than in the terms, that "Compounded medications are not FDA-approved. This compound has not been evaluated by the FDA for safety or efficacy."
It names the state it cannot serve — Arkansas — rather than claiming all fifty and qualifying it in a document nobody opens.
And it publishes who it is: Strut Health, LLC, 701 Commerce Street, Dallas, with Dr. Simal Patel, MD as founder and CEO.
The letter, and what it was actually about
On 20 February 2026 FDA issued warning letter 721448 to Strut Health, LLC dba Strut. 8 It cites two things under FD&C Act 502(a) and 502(bb). The first is that the compounded products "displayed on your website identify 'Strut' on the pictured label, suggesting Strut is the compounder of those drugs when in fact it is not." The second is website language including "Generic Zepbound, Mounjaro."
Both are labelling and advertising findings. The letter alleges nothing about sterility, potency, contamination or product quality, and this review does not treat it as though it did.
Strut acted on it. All three cited phrases are gone from the live site, and the compounding disclaimer now leads the weight-loss pages. What has not happened is a close-out — FDA has issued none, so nearly six months on the letter stands open.
There is an unresolved thread, though, and it is the reason the letter belongs in a review about evidence rather than only in one about marketing. FDA's finding was that the site implies Strut is the compounder when it is not. Strut still does not name who the compounder is — across all 132 pages in its own sitemap, there is no pharmacy name, only "partner pharmacy" and "pharmacy network". And its footer displays ACHC and PCAB badges, both of which are pharmacy accreditations, with no entity, no certificate number and no link. A reader cannot tell whether those badges belong to Strut, to the unnamed pharmacy, or to nobody on the page.
What this means if you are buying
For semaglutide or tirzepatide, Strut is a reasonable place to look and the claims on the pages are broadly supported — appetite suppression and glycaemic control are established at phase 3 for both. 4 5 Check the arithmetic before you agree to anything: the tirzepatide page advertises "as low as $199", its own 30-day card says $325, and the "Just $6.63" printed beneath the $325 is the per-day rate for $199. Thirty days at $325 is $10.83 a day. That card sits under a heading reading "Transparent Pricing".
For sermorelin, understand what you are buying: a molecule with no completed human trial under any name, sold on eight promised outcomes, at $119 a month injectable or $99 for the lozenge — and the lozenge adds an absorption question on top of the evidence question.
For NAD+, the page that is selling it does not appear to know what it is.
For Super Strut, ask which of apomorphine or PT-141 you are being prescribed before you take it, and know that if the answer is PT-141, the approved label for that molecule says it is not indicated for men and not indicated to enhance performance.
Questions
Frequently asked questions
Is there any clinical trial evidence for sermorelin?
No registered trial names it. A ClinicalTrials.gov search on 10 August 2026 returned no interventional record naming sermorelin as the intervention, across six query forms — "sermorelin", "sermorelin acetate", "GHRH(1-29)", "GHRH 1-29", "growth hormone releasing hormone 1-29" and its withdrawn brand name "Geref" — plus a free-text search of every field. The 27 studies the search does return are all different molecules, mostly tesamorelin and GHRH(1-44). In PubMed, sermorelin appears in 24 titles or abstracts and none carries the randomised-controlled-trial or clinical-trial publication type. Those searches were controlled: run identically, tirzepatide returns 158 registry records and 126 trial papers, tesamorelin 17 and 21, bremelanotide 10 and 11. So this is a result, not a failed query. It says nothing about whether sermorelin is safe; it says no registered trial has measured whether it does what it is sold to do.
Why does Strut's NAD+ page call it a peptide?
Because the block was copied from the sermorelin page and not edited. On the sermorelin pages, "A peptide that signals your own pituitary gland — supports your body's natural hormone production" is accurate: sermorelin is a peptide and it does act on the pituitary. On the NAD+ page the same three lines sit under the heading "Meet NAD+", where every one of them is wrong. NAD+ is a dinucleotide, contains no amino acids, and has nothing to do with pituitary signalling. The same page's own opening paragraph gets it right, calling NAD+ "a vital coenzyme". The block is in the served HTML on both the men's and the women's NAD+ pages, so it has shipped twice.
What is actually in Super Strut?
Strut lists four actives: tadalafil, vardenafil, "Apomorphine OR PT-141", and oxytocin. Tadalafil and vardenafil are approved PDE5 inhibitors and are not in question. The third slot is disclosed as a choice between two drugs from different classes — apomorphine is a dopamine agonist, PT-141 (bremelanotide) is a melanocortin receptor agonist — and nothing on the page tells you which one you receive. If it is PT-141, the approved product containing that molecule is Vyleesi, whose label carries two consecutive Limitations of Use: "not indicated for the treatment of HSDD in postmenopausal women or in men" and "not indicated to enhance sexual performance". Its two phase 3 trials enrolled 723 and 714 premenopausal women. This site does not tell you what to take; it reports what the label and the registry say.
Does the FDA warning letter mean Strut's products are unsafe?
The letter does not say that, and neither does this review. Warning letter 721448, issued 20 February 2026, cites Strut under FD&C Act 502(a) and 502(bb) for labelling and advertising: that its pictured labels suggested Strut was the compounder "when in fact it is not", and that its site used phrases like "Generic Zepbound, Mounjaro". There is no allegation about sterility, potency, contamination or product quality anywhere in it. Strut has removed all three cited phrases and now leads its weight-loss pages with the not-FDA-approved disclaimer. FDA has issued no close-out, so the letter is still open. A letter discloses; only a shutdown, injunction or seizure would disqualify, and none of those has happened.
Which pharmacy compounds Strut's peptides?
Strut does not say. Across the 132 pages in its own sitemap there is no pharmacy name — only "partner pharmacy", "pharmacy network" and "U.S. Pharmacy & Medicines". That gap is more pointed here than elsewhere, because the open FDA letter is specifically about the site implying Strut is the compounder when it is not; the correction it invites is naming who is. The footer shows ACHC and PCAB badges, both pharmacy accreditations, with no accredited entity, no certificate number and no link, so there is no way to tell whose accreditation is being displayed. No certificate of analysis, batch record, potency result or sterility result is published for any product.
What does Strut actually cost?
The advertised figures are $119 for injectable sermorelin (9 mg at 2.5 mg/mL), $99 for thirty sermorelin lozenges, $149 for NAD+ (500 mg at 200 mg/mL), "as low as" $149 for injectable semaglutide, "as low as" $199 for injectable tirzepatide, and $79 a month for ten Super Strut tablets. Two caveats. Every one of those is a subscription rate — Strut bills "every 30 or 90 days" under its Terms §20, and no one-off price is reachable, because checkout collects an email address and phone number before showing a total. And the tirzepatide page does not agree with itself: its own 30-day supply card reads $325, with "Just $6.63" printed underneath, which is the per-day rate for $199 rather than for $325. At $325 the daily figure is $10.83.
Glossary
Key terms
Show definitions
- Sermorelin
- A synthetic fragment of growth hormone-releasing hormone, GHRH(1-29). It signals the pituitary to release the body's own growth hormone rather than supplying growth hormone directly. Once approved in the US as Geref; that approval has been withdrawn, and no current ClinicalTrials.gov record names sermorelin as an intervention.
- Tesamorelin
- A different GHRH analogue, marketed as Egrifta and approved for HIV-associated lipodystrophy. It appears throughout registry searches for sermorelin because the two are related, and it is the molecule those trials actually tested. It is not what Strut sells.
- Limitations of Use
- A section of an FDA-approved label stating what a drug is specifically not indicated for. It is a boundary on the approval itself, not a caution. Vyleesi's names men, postmenopausal women, and performance enhancement.
- Close-out
- A notice FDA issues when it is satisfied a firm has corrected the violations in a warning letter. It is published in its own column of the warning-letter index. Strut's letter has none, so it remains open.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Strut Health's own pages on the date stamped against it, and the URL it came from is published beside it.
Trials read from the registry
Phase, status and enrolment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 8 sources
- US National Library of Medicine (2026). ClinicalTrials.gov v2 search: no interventional record names sermorelin as the intervention. Six query forms run — "sermorelin", "sermorelin acetate", "GHRH(1-29)", "GHRH 1-29", "growth hormone releasing hormone 1-29", "Geref" — plus a free-text pass. The 27 studies returned are tesamorelin, GHRH(1-44) or unspecified diagnostic GHRH. Positive controls in the same pass: tirzepatide 158 records, tesamorelin 17, bremelanotide 10. Run 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/search?intr=sermorelin
- US National Library of Medicine (2026). PubMed search: "sermorelin"[tiab] returns 24 records; "sermorelin"[tiab] AND randomized controlled trial[pt] returns 0, as does the clinical trial publication type. Positive controls in the same pass: tirzepatide 126, tesamorelin 21, bremelanotide 11. Run 2026-08-10.. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin%5Btiab%5D+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). ClinicalTrials.gov v2 and PubMed searches for injected NAD+ in humans: no completed randomised trial supporting a restoration-of-function claim, and zero randomised-controlled-trial publications for nicotinamide adenine dinucleotide combined with injection or subcutaneous administration. The human literature concerns oral precursors. Run 2026-08-10.. ClinicalTrials.gov / PubMed. https://clinicaltrials.gov/search?intr=NAD%2B
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
- US Food and Drug Administration (2026). VYLEESI (bremelanotide) injection — prescribing information, section 1, Limitations of Use: "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men. VYLEESI is not indicated to enhance sexual performance." Read 2026-08-10.. FDA prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
- US National Library of Medicine (2026). RECONNECT Study 1 (NCT02333071, phase 3, completed, n=723) and RECONNECT Study 2 (NCT02338960, phase 3, completed, n=714) — bremelanotide in premenopausal women with hypoactive sexual desire disorder. Read 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT02333071
- US Food and Drug Administration (2026). Warning Letter 721448 to Strut Health, LLC dba Strut, issued 2026-02-20. Cited under FD&C Act 502(a) and 502(bb) for labelling and advertising; no product-quality allegation. No close-out as of 2026-08-10.. FDA warning letters. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/strut-health-llc-dba-strut-721448-02202026
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.